Royal Marsden Hospital
Terminated study’s ‘challenges’ may guide future trials of MRD-guided breast cancer therapy
SAN ANTONIO — A randomized phase 3 clinical trial designed to assess whether circulating tumor DNA surveillance could be used to help prevent breast cancer recurrence closed early due to a lack of patients eligible for randomization.
Nivolumab plus ipilimumab offers ‘potential for cure’ in advanced melanoma
The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.
Retifanlimab regimen improves outcomes in advanced anal cancer
The addition of retifanlimab to standard first-line chemotherapy improved outcomes for certain patients with advanced squamous cell carcinoma of the anal canal, according to randomized phase 3 study results presented at ESMO Congress.
Longer follow-up supports benefit of abemaciclib for high-risk breast cancer
SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time, according to randomized phase 3 results presented at San Antonio Breast Cancer Symposium.
Long-course ADT plus radiotherapy provides survival benefit after prostatectomy
Long-course androgen depravation therapy extended metastasis-free survival compared with short-course ADT when added to radiotherapy after radical prostatectomy, results of the randomized phase 3 RADICALS-HD trial showed.
Adjuvant pembrolizumab extends DFS in resected early-stage non-small cell lung cancer
Pembrolizumab significantly extended DFS among patients with completely resected stage IB to stage III non-small cell lung cancer, irrespective of PD-L1 expression, according to a study presented during an ESMO Virtual Plenary session.
Data support third COVID-19 vaccine dose for some patients with cancer
COVID-19 variants pose a greater threat to certain patients with cancer, particularly those with hematologic malignancies, confirming the need to promote vaccination within this population, according to data presented at ESMO Congress 2021.
Durability of lifileucel linked to duration of immune checkpoint inhibitor use in melanoma
Each 6-month decrease in exposure to immune checkpoint inhibitors nearly doubled the duration of response to therapy with lifileucel among patients with metastatic melanoma, according to long-term results of a phase 2 study.
Gene-edited T-cell therapy shows ‘promising efficacy’ for rare sarcomas
Nearly 40% of patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma responded to therapy with afamitresgene autoleucel, according to results of a phase 2 study.
Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer
The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy alone among patients with previously untreated advanced esophageal squamous cell carcinoma, according to phase 3 study findings.